Artwork

Content provided by Healio. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Healio or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

DME/Retina Edition: Top Headlines for Week of July 8, 2024

10:22
 
Share
 

Manage episode 428373684 series 3560281
Content provided by Healio. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Healio or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

In this edition, FDA approves Vabysmo prefilled syringe for retinal diseases, 4D Molecular Therapeutics updates on retinal disease candidates and more. Read the full coverage here:

FDA approves Vabysmo prefilled syringe for retinal diseases

VIDEO: 4D Molecular Therapeutics shares update on retinal disease candidates

FDA approves Eylea biosimilar FYB203/Ahzantive

VIDEO: Oral therapy improves central subfield thickness in DME in early-stage study

ANI Pharmaceuticals to acquire Alimera Sciences

References:

Agrawal R. RZ402: Initial results from a phase 2 study of a novel, orally administered PKal inhibitor in patients with DME. Presented at: Clinical Trials at the Summit; June 8, 2024; Park City, Utah.

Healio Interviews

Press Release

Press Release

Press Release

Editor's note: At the 1:35 mark, we mention that Vabysmo will be available later this year. This specifically applies to Vabysmo pre-filled syringe. There is a currently available formulation already on the market.

  continue reading

118 episodes

Artwork
iconShare
 
Manage episode 428373684 series 3560281
Content provided by Healio. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Healio or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

In this edition, FDA approves Vabysmo prefilled syringe for retinal diseases, 4D Molecular Therapeutics updates on retinal disease candidates and more. Read the full coverage here:

FDA approves Vabysmo prefilled syringe for retinal diseases

VIDEO: 4D Molecular Therapeutics shares update on retinal disease candidates

FDA approves Eylea biosimilar FYB203/Ahzantive

VIDEO: Oral therapy improves central subfield thickness in DME in early-stage study

ANI Pharmaceuticals to acquire Alimera Sciences

References:

Agrawal R. RZ402: Initial results from a phase 2 study of a novel, orally administered PKal inhibitor in patients with DME. Presented at: Clinical Trials at the Summit; June 8, 2024; Park City, Utah.

Healio Interviews

Press Release

Press Release

Press Release

Editor's note: At the 1:35 mark, we mention that Vabysmo will be available later this year. This specifically applies to Vabysmo pre-filled syringe. There is a currently available formulation already on the market.

  continue reading

118 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide